Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells

Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells

(2016) Zeynep Firtina Karagonlar et al.   CANCER SCIENCE

Personalized therapy for hepatocellular carcinoma: Where are we now?

(2016) Stephen L. Chan et al.   CANCER TREATMENT REVIEWS

Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma

(2016) Jordi Bruix et al.   GASTROENTEROLOGY

c-Met–mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma

(2016) Menggui Huang et al.   JOURNAL OF CLINICAL INVESTIGATION

Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer

(2016) C. Stottrup et al.   MOLECULAR CANCER THERAPEUTICS

Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling

(2016) P-F Zhang et al.   Cell Death & Disease

Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice

(2016) Junjie Hu et al.   Scientific Reports

Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma

(2015) L. M. Phan et al.   CANCER RESEARCH

Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

(2015) C. Krepler et al.   CLINICAL CANCER RESEARCH

A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies

(2015) S. Gupta et al.   CLINICAL CANCER RESEARCH

Novel drugs in clinical development for hepatocellular carcinoma

(2015) Oliver Waidmann et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

AKT Inhibition Promotes Nonautonomous Cancer Cell Survival

(2015) Salony et al.   MOLECULAR CANCER THERAPEUTICS

Hepatocellular carcinoma: Where there is unmet need

(2015) Manojkumar Bupathi et al.   Molecular Oncology

Small molecule inhibitor of c-Met (PHA665752) suppresses the growth of ovarian cancer cells and reverses cisplatin resistance

(2015) Enze Li et al.   TUMOR BIOLOGY

Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma

(2015) Xiufeng Jiang et al.   Oncotarget

MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A

(2015) Katsuya Ohta et al.   Oncotarget

INC280, an orally available small molecule inhibitor of c-MET, reduces migration and adhesion in ovarian cancer cell models

(2015) Kim Moran-Jones et al.   Scientific Reports

2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2

(2014) Li Ma et al.   CANCER LETTERS

Resistance to targeted cancer drugs through hepatocyte growth factor signaling

(2014) Guus JJE Heynen et al.   CELL CYCLE

Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET

(2014) Q. Xiang et al.   CLINICAL CANCER RESEARCH

Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design

(2014) J. M. Llovet et al.   CLINICAL CANCER RESEARCH

Tivantinib: critical review with a focus on hepatocellular carcinoma

(2014) Elena Rota Caremoli et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by Switching Protective Autophagy to Autophagic Cell Death in Hepatocellular Carcinoma

(2014) B. Zhai et al.   MOLECULAR CANCER THERAPEUTICS

The Met receptor tyrosine kinase: A key player in oncogenesis and drug resistance

(2014) Christiane R. Maroun et al.   PHARMACOLOGY & THERAPEUTICS

Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib

(2013) Maria Serova et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068

(2013) Y. Yan et al.   CLINICAL CANCER RESEARCH

Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?

(2013) Carmen Berasain   GUT

Met as a therapeutic target in HCC: Facts and hopes

(2013) Silvia Giordano et al.   JOURNAL OF HEPATOLOGY

Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance

(2012) Edita Aksamitiene et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy

(2012) George R. Blumenschein et al.   JOURNAL OF CLINICAL ONCOLOGY

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

(2012) Armando Santoro et al.   LANCET ONCOLOGY

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

MET: a promising anticancer therapeutic target

(2012) Solange Peters et al.   Nature Reviews Clinical Oncology

AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity

(2011) Sarat Chandarlapaty et al.   CANCER CELL

Management of hepatocellular carcinoma: An update

(2011) Jordi Bruix et al.   HEPATOLOGY

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

(2011) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma

(2011) A.-C. Piguet et al.   MOLECULAR CANCER THERAPEUTICS

HGF-independent potentiation of EGFR action by c-Met

(2011) A M Dulak et al.   ONCOGENE

Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells

(2010) Patrizia Sini et al.   Autophagy

Overexpression of von Hippel–Lindau protein synergizes with doxorubicin to suppress hepatocellular carcinoma in mice

(2010) Jizhou Wang et al.   JOURNAL OF HEPATOLOGY

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE